Changes in Hong Kong stocks | Jingfang Pharmaceutical-B (02595) rose more than 8% in the intraday period, and its GFH276 innovative combination therapies were clinically tested

The Zhitong Finance App learned that Jingfang Pharmaceutical-B (02595) rose more than 8% in the intraday period. As of press release, it rose 6.66% to HK$24.02, with a turnover of HK$38.3687 million.

According to the news, Jingfang Pharmaceutical announced that since the third quarter of this year, a number of innovative combination therapies for oral administration of the pan-RAS inhibitor GFH276 have obtained clinical trial permits issued by the domestic CDE or completed the Australian TGA clinical trial registration. Relevant studies cover first-line and post-line treatment of multiple RAS mutation tumors. Some trials have enrolled patients at multiple dose levels.

According to Guojin Securities, Jinfang Pharmaceutical is the leading segment in the domestic RAS field. The product matrix covers KRAS G12C (fluzelase), KRAS G12D (GFH375), Pan-RAS molecular glue (GFH276), and RASADC. Many product progress ranks first in the country and first in the world. It is worth noting that since October 2026, the data for the company's two core products have been implemented intensively.